{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:36:21Z","timestamp":1793316981321,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijbiomac.2026.150730","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:53:25Z","timestamp":1770191605000},"page":"150730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dual-action strategy to reprogram chaperone activity for \u03b1-synuclein aggregate clearance in Parkinson's disease"],"prefix":"10.1016","volume":"347","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2160-9424","authenticated-orcid":false,"given":"Oliwia","family":"Kosz\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-0042","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"So\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-1701","authenticated-orcid":false,"given":"Joanna","family":"Depciuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-2544","authenticated-orcid":false,"given":"Maciej","family":"Maj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.150730_bb0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fneur.2019.00062","article-title":"Motor learning deficits in Parkinson\u2019s disease (PD) and their effect on training response in gait and balance: a narrative review","volume":"10","author":"Olson","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12964-024-01791-8","article-title":"Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways","volume":"22","author":"Kosz\u0142a","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0015","series-title":"Handbook of Clinical Neurology","first-page":"321","article-title":"Prion-like propagation of pathology in Parkinson disease","author":"Volpicelli-Daley","year":"2018"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrm2873","article-title":"Prion-like transmission of protein aggregates in neurodegenerative diseases","volume":"11","author":"Brundin","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","article-title":"Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0030","article-title":"Levodopa treatment patterns in Parkinson\u2019s disease: a retrospective chart review","volume":"6","author":"Navaratnam","year":"2022","journal-title":"Clinical Parkinsonism & Related Disorders"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3233\/JPD-239901","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update","volume":"13","author":"McFarthing","year":"2023","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ana.26073","article-title":"Foslevodopa\/Foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease","volume":"90","author":"Rosebraugh","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.976385","article-title":"Multifunctional role of natural products for the treatment of Parkinson\u2019s disease: at a glance","volume":"13","author":"Rahman","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/4067597","article-title":"Natural compounds for the Management of Parkinson\u2019s disease and attention-deficit\/hyperactivity disorder","volume":"2018","author":"Corona","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105799","article-title":"Unveiling nature\u2019s potential: promising natural compounds in Parkinson\u2019s disease management","volume":"115","author":"Bhusal","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10571-025-01610-9","article-title":"Co-treatment strategy supports neuroprotection by intersecting p62-Keap1-NRF2 and autophagy signaling pathways in the cellular model of Parkinson\u2019s disease","volume":"45","author":"Kosz\u0142a","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2024.141529","article-title":"Analysis of pharmacokinetic profile and ecotoxicological character of cefepime and its photodegradation products","volume":"353","author":"\u017bandarek","year":"2024","journal-title":"Chemosphere"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0070","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s11064-022-03570-8","article-title":"In vitro and in vivo evaluation of antioxidant and neuroprotective properties of antipsychotic D2AAK1","volume":"47","author":"Kosz\u0142a","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00018-016-2340-9","article-title":"Expanding role of molecular chaperones in regulating \u03b1-synuclein misfolding; implications in Parkinson\u2019s disease","volume":"74","author":"Sharma","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0080","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/emm.2007.42","article-title":"Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine","volume":"39","author":"Lee","year":"2007","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5603\/FM.a2022.0068","article-title":"Lithium chloride promotes neural functional recovery after local cerebral ischaemia injury in rats through Wnt signalling pathway activation","volume":"82","author":"Junde","year":"2023","journal-title":"Folia Morphol. (Warsz)"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0090","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1177\/0963689718780930","article-title":"Resveratrol treatment in different time-attenuated neuronal apoptosis after oxygen and glucose deprivation\/Reoxygenation via enhancing the activation of Nrf-2 signaling pathway in vitro","volume":"27","author":"Yang","year":"2018","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2015.00209","article-title":"Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells","volume":"9","author":"Alural","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38631","article-title":"Resveratrol inhibited colorectal cancer progression by reducing oxidative DNA damage by targeting the JNK signaling pathway","volume":"10","author":"Maleki","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135232","article-title":"Effects of resveratrol on the levels of ATP, 5-HT and GAP-43 in the hippocampus of mice exposed to chronic unpredictable mild stress","volume":"735","author":"Shen","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0110","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1093\/brain\/awx275","article-title":"Synaptic phosphorylated \u03b1-synuclein in dementia with Lewy bodies","volume":"140","author":"Colom-Cadena","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbr.2019.03.043","article-title":"Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice","volume":"367","author":"Liu","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/092986708783330692","article-title":"Aggresome formation and neurodegenerative diseases: therapeutic implications","volume":"15","author":"Chin","year":"2008","journal-title":"CMC"},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105527","article-title":"Molecular chaperones and Parkinson\u2019s disease","volume":"160","author":"Hu","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/ars.2007.1866","article-title":"Resveratrol induces the heat-shock response and protects human cells from severe heat stress","volume":"10","author":"Putics","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ijbiomac.2026.150730_bb0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1021\/acschemneuro.3c00571","article-title":"Exploration of resveratrol as a potent modulator of \u03b1-Synuclein fibril formation","volume":"15","author":"Illes-Toth","year":"2024","journal-title":"ACS Chem. Neurosci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026006562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026006562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:11:19Z","timestamp":1772169079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026006562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S0141813026006562"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150730","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-action strategy to reprogram chaperone activity for \u03b1-synuclein aggregate clearance in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150730"}}